Vasculitis & polymyalgia rheumatica
Serine proteinase inhibitor A3 (SERPINA3), FGA, AGP1, ITIH3 and serum amyloid A1 (SAA1) as novel biomarkers for eosinophilic granulomatosis with polyangiitis diagnosis and activity assessment
Authors' conclusion
SERPINA3, FGA, AGP1, ITIH3 and SAA1 were identified as potential biomarkers for EGPA diagnosis and disease activity assessment. Among them, as a single biomarker, SERPINA3 had the best diagnostic performance.
Study context
- Population
- Plasma samples from eosinophilic granulomatosis with polyangiitis (EGPA) patients, disease controls and healthy controls (HCs)discovery 11 EGPA/10 HCs
- Comparison
- EGPA vs HCs and disease controls
- Disease controls (DCs)n = 24reference
- Outcome
- Novel biomarkers for diagnosis and prediction of active EGPA
Methodological detailsproteomic discovery (data-independent acquisition) with ELISA validation, ROC analysis
- Proteomic discovery (data-independent acquisition) with ELISA validation
- ROC analysis
Performance
As reported in the abstract
Diagnostic value of candidate biomarker panels (AUC)
Differentially expressed proteins EGPA vs HC (24 upregulated, 11 downregulated)
35
AUC, SERPINA3 + SAA1 panel, EGPA diagnosis
0.953
AUC, SERPINA3 + FGA + AGP1 + ITIH3 panel, EGPA vs DCs
0.926
Further findings
- AUC, SERPINA3 + AGP1, disease activity assessment
- 0.918
- SERPINA3, FGA and AGP significantly higher in active EGPA and correlated well with disease activity
Original publication
SERPINA3, FGA, AGP1, ITIH3 and SAA1 as novel biomarkers for eosinophilic granulomatosis with polyangiitis diagnosis and activity assessment. Rheumatology (Oxford). Published 29 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →